From approvals to acquisitions, here are eight developments in regenerative medicine to know since March 1.
1. Surgeons at Yale Medicine in New Haven, Conn., are using stem cells to treat some hip conditions to avoid using joint replacements.
2. Ortho Regenerative Technologies named Philippe Deschamps as president and CEO.
3. Zimmer Biomet cemented a multiyear partnership with Biocomposites to exclusively distribute its Genex bone graft substitute in the U.S.
4. Two-year data from a pilot study found the StemSpine regenerative procedure was effective for treating chronic lower back pain.
5. Orthopedic biologic company TheraCell was acquired by Isto Biologics.
6. RTI Surgical, which develops biologic implants, is expanding its facility in Alachua, Fla.
7. Kuros Biosciences' MagenetOs Flex Matrix was cleared by the FDA for use as a bone void filler in the posterolateral spine.
8. The worldwide orthopedic regenerative surgical product market is expected to reach $5.6 billion by 2030, according to Research and Markets.